Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.080
+0.050 (1.65%)
Mar 6, 2026, 4:08 PM HKT
Market Cap7.60B +14.6%
Revenue (ttm)763.16M -3.3%
Net Income-175.20M
EPS-0.17
Shares Out1.04B
PE Ration/a
Forward PEn/a
Dividend0.07 (2.21%)
Ex-Dividend Daten/a
Volume997,000
Average Volume2,012,070
Open3.030
Previous Close3.030
Day's Range3.020 - 3.110
52-Week Range2.130 - 5.290
Beta0.12
RSI47.38
Earnings DateMar 31, 2026

About HKG:1349

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and H... [Read more]

Sector Healthcare
Founded 1996
Employees 899
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1349
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements